BioCryst Pharmaceuticals (NASDAQ: BCRX) CEO reports tax share withholding

Rhea-AI Filing Summary

BioCryst Pharmaceuticals reported that a director who also serves as Chief Executive Officer had 27,368 shares of common stock withheld on December 12, 2025 to satisfy required tax withholding obligations tied to the vesting of previously granted restricted stock units at a price of $7.57 per share.

After this transaction, the insider beneficially owns 1,405,222 shares directly, plus 30,000 shares held in each of two irrevocable trusts for which the insider’s spouse serves as co‑trustee.

The company notes that this tax withholding does not represent an open‑market sale by the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stonehouse Jon P

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		F		27,368(1)	D	$7.57	1,405,222	D
Common Stock								30,000	I	By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
Common Stock								30,000	I	By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.

	/s/ Alane P. Barnes, by power of attorney	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioCryst Pharmaceuticals (BCRX) report on December 12, 2025?

The report shows that a director and Chief Executive Officer had 27,368 shares of BioCryst common stock withheld to cover tax obligations from vesting restricted stock units.

Was the BioCryst (BCRX) CEOs December 2025 transaction an open-market sale of shares?

No. The company explains that the 27,368 shares were withheld by the issuer to satisfy tax withholding obligations and that this transaction does not represent a sale by the reporting person.

How many BioCryst (BCRX) shares does the reporting person own after this tax withholding?

Following the transaction, the insider beneficially owns 1,405,222 shares directly, plus 30,000 shares held in each of two irrevocable trusts where the insiders spouse acts as co-trustee.

What price was used for the BioCryst (BCRX) shares withheld for taxes?

The 27,368 shares of common stock withheld to satisfy tax obligations were valued at a price of $7.57 per share.

What types of securities are covered in this BioCryst (BCRX) insider report?

The report covers non-derivative common stock of BioCryst Pharmaceuticals; the derivative securities table contains no reported derivative transactions in this excerpt.